Clinical trials: Osler-Rendu Disease
Osler-Rendu-Weber Disease, Osler-Rendu Disease
Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia
This study will explore the factors that influence screening behaviors of adults diagnosed with hereditary hemorrhagic telangiectasia (HHT), an inherited condition in which blood vessel defects called arteriovenous malformations…
- Conditions
- Osler-Rendu-Weber Disease, Osler-Rendu Disease, Telangiectasia, Hereditary Hemorrhagic
- Trial name
- NCT00684879
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Rendu Osler Disease, Telangiectasia, Hereditary Hemorrhagic
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).
The recognized manifestations of HHT are all due to abnormalities of vascular structure. Epistaxis and digestive arteriovenous malformations may be responsible for severe hemorrhages in 5% of HHT patients, requiring repeated…
- Trial name
- BABH (NCT03227263)
- Testing
- Bevacizumab, sodium chloride 0.9%
- Where
- 4 sites in France
- Volunteers
- 24 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia (HHT), Pulmonary Hypertension
Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network
High cardiac output secondary to hepatic arteriovenous malformations may be isolated or associated with left heart failure with post-capillary pulmonary hypertension.
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT), Pulmonary Hypertension, Bevacizumab
- Trial name
- BevaHHearT (NCT07445347)
- Testing
- Bevacizumab
- Where
- France
- Volunteers
- 111 people
- Sponsor
- Poitiers University Hospital
Hereditary Hemorrhagic Telangiectasia
Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia
Patients with hereditary hemorrhagic telangiectasia (HHT) suffer from an inherited disorder leading to systemic vascular malformations.
- Trial name
- NCT04469517
- Testing
- hypoxic induced factors
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen
Bevacizimab, HHT
Bevacizumab in the Treatment of HHT
Clinical Study Abstract (Ethics Application) Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant vascular disorder characterized by recurrent intractable epistaxis and multi-organ arteriovenous malformations.
- Trial name
- NCT07828015
- Testing
- Bevacizumab, nasal electrocoagulation., Thalidomide (50mg)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)
Current management strategies for severe and recurrent epistaxis secondary to Hereditary hemorrhagic telangiectasia (HHT) include surgical procedures, and uncomfortable nasal packing, both of which are often only short-term…
- Trial name
- NCT02638012
- Testing
- Floseal, Packing
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Unity Health Toronto
Hereditary Hemorrhagic Telangiectasia
Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary hemorrhagic telangiectasia (HHT, Rendu-Osler-Weber Syndrome) is associated with frequent nosebleeds in the majority of cases.
- Trial name
- TAHHT (NCT01031992)
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- University Hospital, Saarland
Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with…
- Trial name
- DIAMOND (NCT07623525)
- Testing
- DIAG723
- Where
- 11 sites in Australia, Canada and 1 more
- Volunteers
- 93 people
- Sponsor
- Diagonal Therapeutics, Inc.
Rendu Osler Disease, Telangiectasia, Hereditary Hemorrhagic
The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia
Antiangiogenic drugs, such as bevacizumab, are a new treatment strategy in Hereditary Hemorrhagic Telangiectasia (HHT). Its systemic administration in patients with HHT improves liver damage-related symptoms and epistaxis (cases…
- Trial name
- ELLIPSE (NCT01507480)
- Testing
- Bevacizumab
- Volunteers
- 42 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia, HHT
CHORUS - Comprehensive HHT Outcomes Registry of the United States (Formerly OUR HHT Registry)
The goal of this study is to better understand HHT, the symptoms and complications it causes ("outcomes") and how the disease impacts people's lives.
- Conditions
- Hereditary Hemorrhagic Telangiectasia, HHT, Arteriovenous Malformation of Brain
- Trial name
- NCT04150822
- Testing
- Registry and Saliva sample
- Where
- Canada
- Volunteers
- 296 people
- Sponsor
- Unity Health Toronto
Anemia, Liver Disease
Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia
The purpose of the study is to evaluate the safety and tolerability of pegylated interferon alpha-2b (PEG-Intron) in patients with severe complications related to Hereditary hemorrhagic telangiectasia (HHT).
- Conditions
- Anemia, Liver Disease, Hypoxemia
- Trial name
- NCT00588146
- Testing
- Pegylated Interferon Alpha2b, Standard care
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Hereditary Hemorrhagic Telangiectasia
Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia
OBJECTIVES: I. Evaluate migraine prophylaxis with soy protein isolate in patients with hereditary hemorrhagic telangiectasia. II.
- Trial name
- NCT00004654
- Testing
- soy protein isolate
- Volunteers
- 60 people
- Sponsor
- National Center for Research Resources (NCRR)
Hereditary Hemorrhagic Telangiectasia
Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial
Hereditary hemorrhagic telangiectasia (HHT) is associated with recurrent epistaxis in 90% of cases. Good response to hormone treatment has been documented, although its use remains controversial.
- Trial name
- NCT00375622
- Testing
- Tamoxifen
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center
HHT, Hereditary Hemorrhagic Telangiectasia
Intranasal Bevacizumab for HHT-Related Epistaxis
This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis when used in conjunction with bipolar…
- Conditions
- HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds
- Trial name
- NCT02389959
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Hereditary Hemorrhagic Telangiectasia (HHT)
Description of the Impact of Symptoms on Quality of Life in HHT Disease: DISQUO
In 2017, the ELECT-RO study led, firstly, to the creation of a tool to measure quality of life (QoL) specific to HHT (hereditary haemorrhagic telangiectasia disease), QoL-HHT, based on patients' experiences, their representations…
- Trial name
- DISQUO (NCT07191639)
- Testing
- completion of the QOL-HHT questionnaire
- Where
- France
- Volunteers
- 185 people
- Sponsor
- Hospices Civils de Lyon
Telangiectasia, Hereditary Hemorrhagic
Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia
In this study the investigators will obtain histological samples from people with hereditary haemorrhagic telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome).
- Trial name
- NCT00733655
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Imperial College London
Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT).
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis
- Trial name
- CHORUS (NCT06259292)
- Where
- 16 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Cure HHT
Hereditary Haemorrhagic Telangiectasia, Liver Transplant
Recurrence of Hereditary Hemorrhagic Telangiectasia (HHT) After Liver Transplantation
Liver transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiectasia (HHT) with severe hepatic involvement.
- Trial name
- HHT (NCT03942315)
- Testing
- Data collection from standard follow-up after liver transplant
- Volunteers
- 14 people
- Sponsor
- Hospices Civils de Lyon
Hereditary Hemorrhagic Telangiectasia, Epistaxis
Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT
Compare the frequency of epistaxis and quality of life related to nasal bleeding in patients with HHT colonized with sataphylococo before and after being treated with mupirocin ointment.
- Trial name
- NCT02963129
- Testing
- Mupirocin
- Where
- 2 sites in Argentina
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Italiano de Buenos Aires
Telangiectasia, Hereditary Hemorrhagic
Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia
This study will investigate whether pazopanib can reduce epistaxis and improve anaemia in subjects with hereditary haemorrhagic telangiectasia (HHT) at a dose that is well tolerated. The study will have 2 parts.
- Trial name
- NCT02204371
- Testing
- Pazopanib
- Where
- 6 sites in United States, Canada
- Volunteers
- 7 people
- Sponsor
- GlaxoSmithKline